Paul Varki - 06 May 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
07 May 2026, 16:18:26 UTC
Prior SEC filing
02 Mar 2026
Next SEC filing
26 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christopher Sullivan, Attorney-in-Fact

Key filing fact

Paul Varki filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 07 May 2026.

Key facts

  • This page summarizes Paul Varki's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
  • 9 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 07 May 2026, 16:18.

Change

  • Previous filing in this sequence was filed on 02 Mar 2026.
  • Current net transaction value: -$1,513,673.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001677896 Primary reporting owner

VARKI PAUL

Relationship
Chief Legal Officer
Address
C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE
Signature
/s/ Christopher Sullivan, Attorney-in-Fact
Signature date
07 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVTX transaction

Common Stock

Options Exercise

Transaction value
Shares
+62,500
Change %
+1720%
Price
$13.43*
Shares after
66,134
Date
06 May 2026
Ownership
Direct
Footnotes
F1
AVTX transaction

Common Stock

Options Exercise

Transaction value
Shares
+12,563
Change %
+19%
Price
$8.04*
Shares after
78,697
Date
06 May 2026
Ownership
Direct
Footnotes
F1
AVTX transaction

Common Stock

Sale

Transaction value
$706,836
Shares
-37,375
Change %
-47%
Price
$18.91
Shares after
41,322
Date
06 May 2026
Ownership
Direct
Footnotes
F1, F2
AVTX transaction

Common Stock

Sale

Transaction value
$102,783
Shares
-5,196
Change %
-13%
Price
$19.78
Shares after
36,126
Date
06 May 2026
Ownership
Direct
Footnotes
F1, F3
AVTX transaction

Common Stock

Sale

Transaction value
$484,541
Shares
-22,839
Change %
-63%
Price
$21.22
Shares after
13,287
Date
06 May 2026
Ownership
Direct
Footnotes
F1, F4
AVTX transaction

Common Stock

Sale

Transaction value
$210,029
Shares
-9,253
Change %
-70%
Price
$22.70
Shares after
4,034
Date
06 May 2026
Ownership
Direct
Footnotes
F1, F5
AVTX transaction

Common Stock

Sale

Transaction value
$9,484
Shares
-400
Change %
-9.9%
Price
$23.71
Shares after
3,634
Date
06 May 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVTX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-62,500
Change %
-42%
Price
$0.000000*
Shares after
87,500
Date
06 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
62,500
Exercise price
$13.43
Footnotes
F1, F6
AVTX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-12,563
Change %
-13%
Price
$0.000000*
Shares after
87,437
Date
06 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,563
Exercise price
$8.04
Footnotes
F1, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

Footnote F2

The reported securities were sold in multiple transactions at prices ranging from $18.50 to $19.495. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Footnote F3

The reported securities were sold in multiple transactions at prices ranging from $19.50 to $19.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Footnote F4

The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Footnote F5

The reported securities were sold in multiple transactions at prices ranging from $22.15 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Footnote F6

Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date.

Footnote F7

The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .